Exact Mass: 395.0372

Exact Mass Matches: 395.0372

Found 26 metabolites which its exact mass value is equals to given mass value 395.0372, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Cefdinir

(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C14H13N5O5S2 (395.0358)


Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   
   

Oxaliplatin

(3aR,7aR)-octahydro-2,5-dioxaspiro[cyclohexa[d]1,3-diaza-2-platinacyclopentane-2,1-cyclopentane]-3,4-dione

C8H12N2O4Pt (395.0445)


Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

   
   

n-Phenyl glucosinolate

n-Phenyl glucosinolate

C13H17NO9S2 (395.0345)


   
   

N-[1,3-Dimethyl-2,4-dioxo-6-(methylthio)-1,2,3,4-tetrahydrothieno[3,2-g]pteridine-7-ylcarbonyl]glycine

N-[1,3-Dimethyl-2,4-dioxo-6-(methylthio)-1,2,3,4-tetrahydrothieno[3,2-g]pteridine-7-ylcarbonyl]glycine

C14H13N5O5S2 (395.0358)


   

cefdinir

Fd&c yellow no. 6, calcium lake

C14H13N5O5S2 (395.0358)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic It is used as a food additive .

   
   

3-(4-chlorophenyl)sulfanyl-4-ethylsulfonyl-7-methoxy-2-methyl-1H-indole

3-(4-chlorophenyl)sulfanyl-4-ethylsulfonyl-7-methoxy-2-methyl-1H-indole

C18H18ClNO3S2 (395.0417)


   

3-Desacetyl Cefotaxime Lactone

3-Desacetyl Cefotaxime Lactone

C14H13N5O5S2 (395.0358)


   

(S,S)-Oxaliplatin

(S,S)-Oxaliplatin

C8H12N2O4Pt (395.0445)


   
   

(S)-1,1-binaphthyl-2,3-disulfoniMide

(S)-1,1-binaphthyl-2,3-disulfoniMide

C20H13NO4S2 (395.0286)


   

5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carboxylic acid

5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carboxylic acid

C17H9ClF3N3O3 (395.0285)


   

Keflin

Keflin

C16H15N2O6S2- (395.0372)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

   

N-[6-(diethylsulfamoyl)-1,3-benzothiazol-2-yl]-2-thiophenecarboxamide

N-[6-(diethylsulfamoyl)-1,3-benzothiazol-2-yl]-2-thiophenecarboxamide

C16H17N3O3S3 (395.0432)


   

4-(2,4-dichlorophenoxy)-N-[(1E)-(3-nitrophenyl)methylene]butanohydrazide

4-(2,4-dichlorophenoxy)-N-[(1E)-(3-nitrophenyl)methylene]butanohydrazide

C17H15Cl2N3O4 (395.044)


   

[(3-methoxy-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)carbonyl]{[2-(trifluoromethoxy)phenyl]sulfonyl}azanide

[(3-methoxy-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)carbonyl]{[2-(trifluoromethoxy)phenyl]sulfonyl}azanide

C12H10F3N4O6S- (395.0273)


   

4-chloro-N-(3,5-dihydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide

4-chloro-N-(3,5-dihydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide

C16H14ClN3O5S (395.0343)


   

2-(4-bromophenyl)-N-[(2-chloro-3,4-dimethoxyphenyl)methyl]-1-cyclopropanamine

2-(4-bromophenyl)-N-[(2-chloro-3,4-dimethoxyphenyl)methyl]-1-cyclopropanamine

C18H19BrClNO2 (395.0288)


   

4-chloro-N-[(2S)-5-hydroxy-2-methyl-3-oxo-2H-indol-1-yl]-3-sulfamoylbenzamide

4-chloro-N-[(2S)-5-hydroxy-2-methyl-3-oxo-2H-indol-1-yl]-3-sulfamoylbenzamide

C16H14ClN3O5S (395.0343)


   
   

LY3020371 (hydrochloride)

LY3020371 (hydrochloride)

C15H16ClF2NO5S (395.0406)


LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM[1]. LY3020371 hydrochloride exerts an antidepressant-like signature in vivo[2].

   

(6r,7r)-3-ethenyl-7-{[(2z)-1-hydroxy-2-(hydroxyimino)-2-(2-imino-3h-1,3-thiazol-4-yl)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(6r,7r)-3-ethenyl-7-{[(2z)-1-hydroxy-2-(hydroxyimino)-2-(2-imino-3h-1,3-thiazol-4-yl)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C14H13N5O5S2 (395.0358)


   

n-(1,1,15,15-tetrachloropentadec-1-en-3,12-diyn-8-yl)ethanimidic acid

n-(1,1,15,15-tetrachloropentadec-1-en-3,12-diyn-8-yl)ethanimidic acid

C17H21Cl4NO (395.0377)